| HOME >> MEDICINE >> TECHNOLOGY |
Disclaimer
The foregoing release contains forward-looking statements that can be
identified by terminology such as "potential", "may", "to be", or similar
expressions, or by express or implied discussions regarding potential new
indications or labelling for Femara or regarding potential future revenues
from Femara. Such forward-looking statements reflect the current views of
the Company regarding future events, and involve known and unknown risks,
uncertainties and other factors that may cause actual results with Femara
to be materially different from any future results, performance or
achievements expressed or implied by such statements. There can be no
guarantee that Femara will be approved for any additional indications or
labelling in any market. Nor can there be any guarantee that Femara will
achieve any particular levels of revenue in the future. In particular,
management's expectations regarding Femara could be affected by, among
other things, unexpected clinical trial results, including unexpected new
clinical data and unexpected additional analysis of existing clinical data;
unexpected regulatory actions or delays or government regulation generally;
the company's ability to obtain or maintain patent or other proprietary
intellectual property protection; competition in general; government,
industry and general public pricing pressures, and other risks and factors
referred to in Novartis AG's current Form 20-F on file with the US
Securities and Exchange Commission. Should one or more of these risks or
uncertainties materialize, or should underlying assumptions prove
incorrect, actual results may vary materially from those anticipated,
believed, estimated or expected. Novartis is providing the information in
this press release as of this date and does not undertake any obligation to
update any forward-looki
'/>"/>
| SOURCE Novartis Pharmaceuticals Corporation Copyright©2008 PR Newswire. All rights reserved |